Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed

Brian R. Weston

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9872-1687; OpenAlex author ID A5070234451. Sources: ClinicalTrials.gov.

Their work

Papers
9
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2012: 1 trial · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers

Papers 9

  1. Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB. Co-author DOI 10.1002/cncy.22533↗
  2. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  3. Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. Co-author DOI 10.1158/1078-0432.ccr-20-2667↗
  4. Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Co-author DOI 10.1158/1078-0432.ccr-20-3925↗
  5. Quality of life impact of EUS in patients at risk for developing pancreatic cancer. Co-author DOI 10.4103/eus.eus_56_19↗
  6. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1200/po.19.00001↗
  7. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6807-9↗
  8. Pancreatic cancer screening in high-risk individuals with germline genetic mutations. Co-author DOI 10.1016/j.gie.2017.12.019↗
  9. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗

Trials 1

  1. Comparison of a Novel 22-gauge Core Biopsy Needle Principal investigator NCT01598194↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 8 shared papers, 2017–2022 · strength 0.77
  2. Manoop S. Bhutani · 7 shared papers, 2017–2022 · strength 0.70
  3. Jeffrey H. Lee · 6 shared papers, 2017–2022 · strength 0.53
  4. Matthew H. G. Katz · 5 shared papers, 2017–2022 · strength 0.40
  5. Huamin Wang · 4 shared papers, 2017–2022 · strength 0.30
  6. Robert A. Wolff · 4 shared papers, 2017–2022 · strength 0.30
  7. Eugene Jon Koay · 4 shared papers, 2017–2022 · strength 0.30
  8. Jeffrey E. Lee · 4 shared papers, 2017–2022 · strength 0.30
  9. William A. Ross · 3 shared papers, 2017–2022 · strength 0.27
  10. Jason B. Fleming · 3 shared papers, 2017–2022 · strength 0.23
  11. Alexander Semaan · 2 shared papers, 2021 · strength 0.22
  12. Maria E. Monberg · 2 shared papers, 2021 · strength 0.22
  13. Jaewon James Lee · 2 shared papers, 2021 · strength 0.22
  14. Paola A. Guerrero · 2 shared papers, 2021 · strength 0.22
  15. Vincent Bernard · 2 shared papers, 2021 · strength 0.22
  16. Emmanuel S. Coronel · 2 shared papers, 2018–2022 · strength 0.22
  17. Florencia M. McAllister · 2 shared papers, 2020–2022 · strength 0.21
  18. Rachna T. Shroff · 3 shared papers, 2017–2019 · strength 0.19
  19. Milind M. Javle · 3 shared papers, 2017–2019 · strength 0.19
  20. Eric Peter Tamm · 3 shared papers, 2017–2019 · strength 0.19
  21. Laura R. Prakash · 3 shared papers, 2017–2019 · strength 0.19
  22. Priya Bhosale · 3 shared papers, 2017–2019 · strength 0.19
  23. Gauri Rajani Varadhachary · 3 shared papers, 2017–2019 · strength 0.19
  24. David R. Fogelman · 3 shared papers, 2017–2019 · strength 0.19
  25. Ching-Wei David Tzeng · 2 shared papers, 2019–2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.